

#### IV. Electronic Access

Persons with access to the Internet may obtain the document at either <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm> or <http://www.regulations.gov>.

Dated: May 1, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014-10409 Filed 5-6-14; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2014-N-0001]

#### Science Board to the Food and Drug Administration; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Science Board to the Food and Drug Administration (Science Board).

*General Function of the Committee:* The Science Board provides advice primarily to the Commissioner of Food and Drugs and other appropriate officials on specific complex scientific and technical issues important to FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments including those in regulatory science; and input into the Agency's research agenda; and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency sponsored intramural and extramural scientific research programs.

*Date and Time:* The meeting will be held on June 4, 2014, from approximately 8:30 a.m. until 4:30 p.m.

*Location:* FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503, sections B and C), Silver Spring, MD 20993. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: <http://www.fda.gov/AdvisoryCommittees/default.htm>; under the

heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

*Contact Person:* Martha Monser, Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 4286, Silver Spring, MD 20993, 301-796-4627, [martha.monser@fda.hhs.gov](mailto:martha.monser@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at <http://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

*Agenda:* On June 4, 2014, the Science Board will discuss and make recommendations on the draft final report from the Center for Biologics Evaluation and Research's postmarketing safety review subcommittee. The committee will be asked to support forming a new subcommittee to evaluate the Commissioner's Fellowship Program. The committee will be presented with an overview of current issues surrounding heparin sourcing issues for discussion. A recipient of one of the fiscal year 2013 Scientific Achievement Awards (selected by the Science Board) will provide an overview of the activities for which the award was given.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact

person on or before May 28, 2014. Oral presentations from the public will be scheduled between approximately 3 p.m. and 4 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 20, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 21, 2014.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Martha Monser at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 1, 2014.

**Jill Hartzler Warner,**

*Acting Associate Commissioner for Special Medical Programs.*

[FR Doc. 2014-10436 Filed 5-6-14; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human

Services (HHS), Health Resources and Services Administration (HRSA) (60 FR 56605, as amended November 6, 1995; as last amended at Vol. 79, FR 18299–18300 dated April 1, 2014).

This notice reflects organizational changes to the Health Resources and Services Administration. This notice updates the functional statement for the Office of Federal Assistance Management (RJ), Division of Financial Integrity (RJ1). Specifically, this notice restructures the functions of the Division of Financial Integrity (RJ1) to serve as the focal point for resolving audit findings and ensuring compliance with program requirements.

### Chapter RJ—Office of Federal Assistance Management

#### Section RJ–20, Functions

Delete the functional statement for the Division of Financial Integrity (RJ1), and replace in its entirety.

#### Division of Financial Integrity (RJ1)

(1) Coordinates Agency-wide efforts addressing HHS's Program Integrity Initiative; (2) serves as the Agency's focal point for resolving audit findings on HRSA programs resulting from the A–133 audits; (3) conducts financial reviews of grantee's use of HRSA funds; (4) conducts the pre-award financial assessment of HRSA grantees; (5) conducts the pre-award and post-award review of grant applicant's and grantee's accounting systems; (6) conducts ad hoc studies and reviews related to the financial integrity of the HRSA business processes related to assistance programs; (7) conducts 340B program audits of covered entities to ensure program integrity and compliance with 340B program requirements; (8) serves as the Agency's liaison with the Office of Inspector General for issues related to grants; (9) coordinates the Agency's response to the HHS Office of Inspector General Hotline complaints reporting possible fraudulent fiscal activities pertaining to HRSA grant funds; and (10) establishes an assessment model for grantee oversight.

#### Section RJ–30, Delegations of Authority

All delegations of authority and re-delegations of authority made to HRSA officials that were in effect immediately prior to this reorganization, and that are consistent with this reorganization, shall continue in effect pending further re-delegation.

This reorganization is effective upon date of signature.

Dated: April 25, 2014.

**Mary K. Wakefield,**

*Administrator.*

[FR Doc. 2014–10477 Filed 5–6–14; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Advisory Board; *ad Hoc* Subcommittee on Global Cancer Research.

*Open:* June 22, 2014, 6:15 p.m. to 7:45 p.m.

*Agenda:* Discussion on Global Cancer Research.

*Place:* Hyatt Regency Bethesda, Cabinet and Judiciary Rooms, One Bethesda Metro Center, Bethesda, Maryland 20814.

*Contact Person:* Dr. Edward Trimble, Executive Secretary, NCAB *ad Hoc* Subcommittee on Global Cancer Research, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W–562, Bethesda, MD 20892, (240) 276–5796, [trimblet@mail.nih.gov](mailto:trimblet@mail.nih.gov).

*Name of Committee:* National Cancer Advisory Board; Subcommittee on Budget and Planning.

*Open:* June 22, 2014, 8:00 p.m. to 9:30 p.m.

*Agenda:* Discussion on Budget and Planning.

*Place:* Hyatt Regency Bethesda, Cabinet and Judiciary Rooms, One Bethesda Metro Center, Bethesda, Maryland 20814.

*Contact Person:* Patrick O. McGarey, Executive Secretary, NCAB Subcommittee on

Budget and Planning, National Cancer Institute, National Institutes of Health, Building 31, 31 Center Drive, Room 11A16, Bethesda, MD 20892, (301) 435–2612, [mcgareypo@mail.nih.gov](mailto:mcgareypo@mail.nih.gov).

*Name of Committee:* National Cancer Advisory Board and NCI Board of Scientific Advisors.

*Open:* June 23, 2014, 9:00 a.m. to 3:30 p.m.

*Agenda:* Joint meeting of the National Cancer Advisory Board, and NCI Board of Scientific Advisors; NCI Board of Scientific Advisors Concepts Review, NCI Director's report, and presentations.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 9606 Medical Center Drive, Room 7W–444, Bethesda, MD 20892, (240) 276–6340.

*Name of Committee:* National Cancer Advisory Board.

*Closed:* June 23, 2014, 3:30 p.m. to 5:00 p.m.

*Agenda:* Review of NCAB Grant Applications.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 9606 Medical Center Drive, Room 7W–444, Bethesda, MD 20892, (240) 276–6340.

*Name of Committee:* National Cancer Advisory Board and NCI Board of Scientific Advisors.

*Open:* June 24, 2014, 9:00 a.m. to 12:00 p.m.

*Agenda:* Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors.

*Place:* National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 9606 Medical Center Drive, Room 7W–444, Bethesda, MD 20892, (240) 276–6340.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: NCAB: [deainfo.nci.nih.gov/advisory/ncab.htm](http://deainfo.nci.nih.gov/advisory/ncab.htm), BSA: [deainfo.nci.nih.gov/advisory/bsa/bsa.htm](http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm),